ClinicalTrials.gg
CompletedNCT06615869Updated Jul 11, 2025

A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)

A Phase 1 interventional study of Molnupiravir in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 8 months ago, and no results have been posted to the registry.
  • Registered 1 year 8 months after the study started (first participant enrolled Jan 2023, registered Sep 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The goal of the study is to learn what happens to different forms of molnupiravir (MOV) medications in a healthy person's body over time when taken on an empty stomach or with food. Researchers will compare the amount of MOV in the healthy person's body over time when different forms of medications are given.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

- Has (BMI) ≥18 kg/m\^2 and ≤32 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • History of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
  • History of significant multiple and/or severe allergies (eg, food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (ie, systemic allergic reaction) to prescription or nonprescription drugs or food.
  • Positive test(s) for surface antigen (HBsAg), antibodies or (HIV).
  • History of a major surgery.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Molnupiravir Treatment A

    Participants receive molnupiravir reference capsule.

    Drug: Molnupiravir

  • Experimental
    Molnupiravir Treatment B

    Participants receive molnupiravir Formulation 1.

    Drug: Molnupiravir

  • Experimental
    Molnupiravir Treatment C

    Participants receive molnupiravir Formulation 1 after a high-fat meal.

    Drug: Molnupiravir

  • Experimental
    Molnupiravir Treatment D

    Participants receive molnupiravir Formulation 2.

    Drug: Molnupiravir

Interventions

  • Oral Administration.

    Also known as: MK-4482, MOV, LAGEVRIO, EIDD-2801

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of N-Hydroxycitidine (NHC) in plasma: Treatment A versus Treatment B

    AUC0-inf of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  2. Area Under the Concentration-Time Curve From Time Zero to last measurable timepoint (AUC0-last) of NHC in plasma: Treatment A versus Treatment B

    AUC0-last of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  3. Area Under the Concentration-Time Curve From Time Zero to 12 hours (AUC0-12) of (NHC) in plasma: Treatment A versus Treatment B

    AUC0-12 of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 12 hours postdose

  4. Maximum plasma concentration (Cmax) of NHC: Treatment A versus Treatment B

    Cmax of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  5. Time to maximum plasma concentration (Tmax) of NHC: Treatment A versus Treatment B

    Tmax of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  6. Apparent terminal half-life (t1/2) of NHC in plasma: Treatment A versus Treatment B

    t1/2 of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  7. Apparent Clearance (CL/F) of NHC in plasma: Treatment A versus Treatment B

    CL/F of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  8. Apparent volume of distribution during terminal phase (Vz/F) of NHC in plasma: Treatment A versus Treatment B

    Vz/F of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

Secondary outcomes

  1. AUC0-inf of NHC in plasma: Treatment B versus Treatment C

    AUC0-inf of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  2. AUC0-last of NHC in plasma: Treatment B versus Treatment C

    AUC0-last of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  3. AUC0-12 of NHC in plasma: Treatment B versus Treatment C

    AUC0-12 of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 12 hours postdose

  4. Cmax of NHC in plasma: Treatment B versus Treatment C

    Cmax of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  5. Tmax of NHC in plasma: Treatment B versus Treatment C

    Tmax of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  6. t1/2 of NHC in plasma: Treatment B versus Treatment C

    t1/2 of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  7. CL/F of NHC in plasma: Treatment B versus Treatment C

    CL/F of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  8. Vz/F of NHC in plasma: Treatment B versus Treatment C

    Vz/F of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  9. AUC0-inf of NHC in plasma: Treatment D versus Treatment A

    AUC0-inf of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  10. AUC0-last of NHC in plasma: Treatment D versus Treatment A

    AUC0-last of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  11. AUC0-12 of NHC in plasma: Treatment D versus Treatment A

    AUC0-12 of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 12 hours postdose

  12. Cmax of NHC in plasma: Treatment D versus Treatment A

    Cmax of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  13. Tmax of NHC in plasma: Treatment D versus Treatment A

    Tmax of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  14. t1/2 of NHC in plasma: Treatment D versus Treatment A

    t1/2 of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  15. CL/F of NHC in plasma: Treatment D versus Treatment A

    CL/F of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  16. Vz/F of NHC in plasma: Treatment D versus Treatment A

    Vz/F of NHC in plasma will be determined.

    Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose

  17. Number of participants who experience one or more adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~ 38 days

  18. Number of participants who discontinue study intervention due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~ 38 days

07

Study locations

1 site
  • QPS-MRA, LLC-Early Phase (Site 0002)
    South Miami, Florida 33143, United States
08

References and documents

Publications

  • Fiore JL, Jin Y, Heimbach T, Patel SR, Zhao T, Matthews CZ, Pagnussat S, Maas BM, Cheng MH, Stoch SA. Pharmacokinetics and bioequivalence of a molnupiravir tablet formulation compared with the molnupiravir capsule formulation in healthy adult participants-a randomized, open-label, three-period, crossover study. Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0143424. doi: 10.1128/aac.01434-24. Epub 2025 Feb 6. PubMed 39912659 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Feb 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Sep 27, 2024
StartActual
Jan 20, 2023
Primary completionActual
Feb 27, 2023
CompletionActual
Mar 15, 2023
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06615869
Responsible party
Sponsor
First posted
Sep 27, 2024
Start date
Jan 20, 2023
Primary completion
Feb 27, 2023
Completion
Mar 15, 2023
Last update
Jul 11, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Molnupiravir

Start the discussion